Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel molecular assays for monitoring T cell function after HSCT in two siblings with variants in <i>DCLRE1C</i>.

Journal of human immunity·2026
Same author

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

EBioMedicine·2026
Same author

Viral Immunity in Immunoglobulin Products: Global Immunity Debt and Autoimmunity in the Postpandemic Era.

European journal of immunology·2026
Same author

T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.

British journal of haematology·2025
Same author

Inborn errors of immunity: Manifestation, treatment, and outcome-an ESID registry 1994-2024 report on 30,628 patients.

Journal of human immunity·2025
Same author

Bronchiectasis, Low IgG Levels and Lack of Vaccination are Risk Factors for Covid-19 Hospitalization in X-linked Agammaglobulinemia - A Retrospective Multicenter Study.

Journal of clinical immunology·2025
Same journal

Neurochondrin promotes U5 snRNP maturation by regulating AAR2 release from PRPF8.

Nucleic acids research·2026
Same journal

Elongationless start-stop elements are stress-resilient translation gates that are more repressive than uTranslons.

Nucleic acids research·2026
Same journal

Evolution of the ribosomal exit tunnel through the eyes of the nascent chain.

Nucleic acids research·2026
Same journal

Enhancing the performance and interpretability of epigenetic clocks.

Nucleic acids research·2026
Same journal

FABIAN-variant 2026: improved prediction of the effects of DNA variants on transcription factor binding.

Nucleic acids research·2026
Same journal

Structural and biochemical characterization of Grimontia hollisae thermostable direct hemolysin with DNA reveals first Vibrio hemolysin with nuclease activity.

Nucleic acids research·2026
See all related articles

Related Experiment Video

Updated: Mar 5, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.1K

CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression.

Eman M Zaghloul1,2, Olof Gissberg1, Pedro M D Moreno1,3,4

  • 1Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, SE-141 86 Huddinge, Stockholm, Sweden.

Nucleic Acids Research
|March 24, 2017
PubMed
Summary
This summary is machine-generated.

Researchers developed a novel oligonucleotide therapy targeting the Huntington gene (HTT) to reduce toxic mutant HTT. This approach successfully lowered HTT mRNA and protein levels, offering a potential new treatment for Huntington's disease.

More Related Videos

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.1K
Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy
11:22

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy

Published on: June 27, 2018

8.5K

Related Experiment Videos

Last Updated: Mar 5, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.1K
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.1K
Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy
11:22

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy

Published on: June 27, 2018

8.5K

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Huntington's disease (HD) is a fatal neurodegenerative disorder characterized by motor, cognitive, and psychological impairments.
  • Current HD treatments are purely symptomatic and do not affect disease progression or lifespan.
  • HD pathogenesis involves the expansion of CAG trinucleotide repeats in the Huntingtin gene (HTT), producing toxic mutant HTT (muHTT) mRNA and protein.

Purpose of the Study:

  • To develop a novel therapeutic strategy for Huntington's disease by targeting the expanded CAG trinucleotide repeat DNA in the HTT gene.
  • To investigate the efficacy of oligonucleotides (ONs) in reducing both mutant HTT mRNA and protein levels.
  • To explore the impact of different ON backbone chemistries and delivery methods for potential in vivo applications.

Main Methods:

  • Oligonucleotides (ONs) were designed to directly target the CAG trinucleotide repeat region in the Huntingtin (HTT) gene DNA.
  • The study assessed the knockdown efficiency of both HTT mRNA and protein levels.
  • Researchers examined the phosphorylation of HTT gene-associated RNA-polymerase II and evaluated various ON backbone chemistries and delivery vehicles.

Main Results:

  • A significant and potentially long-term reduction in both HTT mRNA and protein levels was achieved using the novel ON strategy.
  • Diminished phosphorylation of HTT gene-associated RNA-polymerase II suggests reduced transcription downstream of the targeted repeat.
  • Different ON backbone chemistries significantly influenced therapeutic efficiency, and successful delivery was demonstrated using various vehicles and naked uptake.

Conclusions:

  • This novel oligonucleotide-based approach effectively reduces mutant Huntingtin (muHTT) mRNA and protein, representing a promising therapeutic strategy for Huntington's disease.
  • The findings highlight the importance of ON backbone chemistry and delivery methods for therapeutic efficacy.
  • The study provides a foundation for developing in vivo applications of this targeted gene-silencing strategy for Huntington's disease.